Estrogen receptor-alpha 36 mediates the anti-apoptotic effect of estradiol in triple negative breast cancer cells via a membrane-associated mechanism

Public Health Nutrition

Volumn 1843, Issue 11, 2014, Pages 2796-2806

  Chaudhri, Reyhaan A ^a,b   Hadadi, Agreen ^a   Lobachev, Kirill S ^a   Schwartz, Zvi ^c   Boyan, Barbara D ^a,c  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b EMORY UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Anti apoptosis; Breast cancer; Estrogen; Estrogen receptor alpha 36; Plasma membrane; Taxol

Indexed keywords

2 BROMOPALMITIC ACID; CASPASE 3; CYTOCHROME C; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA 36; LYSOPHOSPHATIDIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE D; THAPSIGARGIN; TUNICAMYCIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CALCIUM SIGNALING; CANCER CELL; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DELETION MUTANT; DRUG MECHANISM; EMBRYO; ENDOPLASMIC RETICULUM; EXON; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MYRISTYLATION; NICK END LABELING; PALMITOYLATION; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER;

EID: 84923200019     PISSN: 13689800     EISSN: 14752727     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2014.07.019     Document Type: Article

References (51)

1. Howlader N.A., Krapcho M., Neyman N., Aminou R., Altekruse S.F., Kosary C.L., Ruhl J., Tatalovich Z., Cho H., Mariotto A., Eisner M.P., Lewis D.R., Chen H.S., Feuer E.J. Cronin KA SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations) 2012, National Cancer Institute, Bethesda, MD.
2. Herranz N., Pasini D., Diaz V.M., Franci C., Gutierrez A., Dave N., Escriva M., Hernandez-Munoz I., Di Croce L., Helin K., Garcia de Herreros A., Peiro S. Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Mol. Cell. Biol. 2008, 28:4772-4781.
3. Razandi M., Pedram A., Levin E.R. Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer. Mol. Endocrinol. 2000, 14:1434-1447.
4. Sui M., Huang Y., Park B.H., Davidson N.E., Fan W. Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res. 2007, 67:5337-5344.
5. Kiyotani K., Mushiroda T., Sasa M., Bando Y., Sumitomo I., Hosono N., Kubo M., Nakamura Y., Zembutsu H. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci. 2008, 99:995-999.
6. DiMartino L., Demontis B., Mitchell I.P., Hayward S.W., Deshpande N. A randomized clinical trial to investigate the usefulness of the addition of prednisolone to tamoxifen as adjuvants to mastectomy in primary breast cancer patients with a high risk of recurrence: a preliminary report. Anticancer Res. 1991, 11:869-872.
7. Harris E.E., Correa C., Hwang W.T., Liao J., Litt H.I., Ferrari V.A., Solin L.J. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J. Clin. Oncol. 2006, 24:4100-4106.
8. Wani M.C., Taylor H.L., Wall M.E., Coggon P., McPhail A.T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 1971, 93:2325-2327.
9. Schiff P.B., Horwitz S.B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. U. S. A. 1980, 77:1561-1565.
10. Zhang Y.L., Zhang Z.H., Jiang T.Y., Ayman W., Jing L., Lv H.X., Zhou J.P. Cell uptake of paclitaxel solid lipid nanoparticles modified by cell-penetrating peptides in A549 cells. Pharmazie 2013, 68:47-53.
11. Hartmann J.T., Fels L.M., Knop S., Stolt H., Kanz L., Bokemeyer C. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Invest. New Drugs 2000, 18:281-289.
12. Schmid P., Schippinger W., Nitsch T., Huebner G., Heilmann V., Schultze W., Hausmaninger H., Wischnewsky M., Possinger K. Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. J. Clin. Oncol. 2005, 23:432-440.
13. Thorpe S.M. Immunological quantitation of nuclear receptors in human breast cancer: relation to cytosolic estrogen and progesterone receptors. Cancer Res. 1987, 47:1830-1835.
14. Jatoi I., Chen B.E., Anderson W.F., Rosenberg P.S. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J. Clin. Oncol. 2007, 25:1683-1690.
15. Schneider J., Ruschhaupt M., Buness A., Asslaber M., Regitnig P., Zatloukal K., Schippinger W., Ploner F., Poustka A., Sultmann H. Identification and meta-analysis of a small gene expression signature for the diagnosis of estrogen receptor status in invasive ductal breast cancer. Int. J. Cancer 2006, 119:2974-2979.
16. Fisher B., Redmond C., Brown A., Fisher E.R., Wolmark N., Bowman D., Plotkin D., Wolter J., Bornstein R., Legault-Poisson S., et al. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J. Clin. Oncol. 1986, 4:459-471.
17. Boyan B.D., Sylvia V.L., Frambach T., Lohmann C.H., Dietl J., Dean D.D., Schwartz Z. Estrogen-dependent rapid activation of protein kinase C in estrogen receptor-positive MCF-7 breast cancer cells and estrogen receptor-negative HCC38 cells is membrane-mediated and inhibited by tamoxifen. Endocrinology 2003, 144:1812-1824.
18. Chaudhri R.A., Olivares-Navarrete R., Cuenca N., Hadadi A., Boyan B.D., Schwartz Z. Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-alpha36 (ERalpha36). J. Biol. Chem. 2012, 287:7169-7181.
19. Chaudhri R.A., Schwartz N., Elbaradie K., Schwartz Z., Boyan B.D. Role of ERalpha36 in membrane-associated signaling by estrogen. Steroids 2014, 81:74-80.
20. Wang Z., Zhang X., Shen P., Loggie B.W., Chang Y., Deuel T.F. Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem. Biophys. Res. Commun. 2005, 336:1023-1027.
21. Wang Z., Zhang X., Shen P., Loggie B.W., Chang Y., Deuel T.F. A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:9063-9068.
22. Xie H., Sun M., Liao X.B., Yuan L.Q., Sheng Z.F., Meng J.C., Wang D., Yu Z.Y., Zhang L.Y., Zhou H.D., Luo X.H., Li H., Wu X.P., Wei Q.Y., Tang S.Y., Wang Z.Y., Liao E.Y. Estrogen receptor alpha36 mediates a bone-sparing effect of 17beta-estrodiol in postmenopausal women. J. Bone Miner. Res. 2011, 26:156-168.
23. Rao J., Jiang X., Wang Y., Chen B. Advances in the understanding of the structure and function of ER-alpha36, a novel variant of human estrogen receptor-alpha. J. Steroid Biochem. Mol. Biol. 2011, 127:231-237.
24. Green P.S., Yang S.H., Nilsson K.R., Kumar A.S., Covey D.F., Simpkins J.W. The nonfeminizing enantiomer of 17beta-estradiol exerts protective effects in neuronal cultures and a rat model of cerebral ischemia. Endocrinology 2001, 142:400-406.
25. Rajendran K.G., Lopez T., Parikh I. Estrogenic effect of phenol red in MCF-7 cells is achieved through activation of estrogen receptor by interacting with a site distinct from the steroid binding site. Biochem. Biophys. Res. Commun. 1987, 142:724-731.
26. Berthois Y., Katzenellenbogen J.A., Katzenellenbogen B.S. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:2496-2500.
27. Finckbone V., Oomman S.K., Strahlendorf H.K., Strahlendorf J.C. Regional differences in the temporal expression of non-apoptotic caspase-3-positive Bergmann glial cells in the developing rat cerebellum. Front. Neuroanat. 2009, 3:3.
28. Gulyaeva N.V. Non-apoptotic functions of caspase-3 in nervous tissue. Biochemistry (Mosc) 2003, 68:1171-1180.
29. Sztiller-Sikorska M., Jakubowska J., Wozniak M., Stasiak M., Czyz M. A non-apoptotic function of caspase-3 in pharmacologically-induced differentiation of K562 cells. Br. J. Pharmacol. 2009, 157:1451-1462.
30. Zhao X., Wang D., Zhao Z., Xiao Y., Sengupta S., Zhang R., Lauber K., Wesselborg S., Feng L., Rose T.M., Shen Y., Zhang J., Prestwich G., Xu Y. Caspase-3-dependent activation of calcium-independent phospholipase A2 enhances cell migration in non-apoptotic ovarian cancer cells. J. Biol. Chem. 2006, 281:29357-29368.
31. Sylvia V.L., Walton J., Lopez D., Dean D.D., Boyan B.D., Schwartz Z. 17 beta-estradiol-BSA conjugates and 17 beta-estradiol regulate growth plate chondrocytes by common membrane associated mechanisms involving PKC dependent and independent signal transduction. J. Cell. Biochem. 2001, 81:413-429.
32. Filardo E., Quinn J., Pang Y., Graeber C., Shaw S., Dong J., Thomas P. Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. Endocrinology 2007, 148:3236-3245.
33. Levin E.R. Cellular functions of the plasma membrane estrogen receptor. Trends Endocrinol. Metab. 1999, 10:374-377.
34. Stevis P.E., Deecher D.C., Suhadolnik L., Mallis L.M., Frail D.E. Differential effects of estradiol and estradiol-BSA conjugates. Endocrinology 1999, 140:5455-5458.
35. Hurst-Kennedy J., Zhong M., Gupta V., Boyan B.D., Schwartz Z. 24R,25-Dihydroxyvitamin D3, lysophosphatidic acid, and p53: a signaling axis in the inhibition of phosphate-induced chondrocyte apoptosis. J. Steroid Biochem. Mol. Biol. 2010, 122:264-271.
36. Bryksin A.V., Matsumura I. Overlap extension PCR cloning: a simple and reliable way to create recombinant plasmids. Biotechniques 2010, 48:463-465.
37. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
38. Sylvia V.L., Schwartz Z., Del Toro F., DeVeau P., Whetstone R., Hardin R.R., Dean D.D., Boyan B.D. Regulation of phospholipase D (PLD) in growth plate chondrocytes by 24R,25-(OH)2D3 is dependent on cell maturation state (resting zone cells) and is specific to the PLD2 isoform. Biochim. Biophys. Acta 2001, 1499:209-221.
39. Schwartz Z., Sylvia V.L., Luna M.H., DeVeau P., Whetstone R., Dean D.D., Boyan B.D. The effect of 24R,25-(OH)(2)D(3) on protein kinase C activity in chondrocytes is mediated by phospholipase D whereas the effect of 1alpha,25-(OH)(2)D(3) is mediated by phospholipase C. Steroids 2001, 66:683-694.
40. Sylvia V.L., Boyan B.D., Dean D.D., Schwartz Z. The membrane effects of 17beta-estradiol on chondrocyte phenotypic expression are mediated by activation of protein kinase C through phospholipase C and G-proteins. J. Steroid Biochem. Mol. Biol. 2000, 73:211-224.
41. Derossi D., Williams E.J., Green P.J., Dunican D.J., Doherty P. Stimulation of mitogenesis by a cell-permeable PI 3-kinase binding peptide. Biochem. Biophys. Res. Commun. 1998, 251:148-152.
42. Li L., Haynes M.P., Bender J.R. Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4807-4812.
43. Marino M., Ascenzi P. Membrane association of estrogen receptor alpha and beta influences 17beta-estradiol-mediated cancer cell proliferation. Steroids 2008, 73:853-858.
44. Anania V.G., Coscoy L. Palmitoylation of MIR2 is required for its function. J. Virol. 2011, 85:2288-2295.
45. Susin S.A., Lorenzo H.K., Zamzami N., Marzo I., Snow B.E., Brothers G.M., Mangion J., Jacotot E., Costantini P., Loeffler M., Larochette N., Goodlett D.R., Aebersold R., Siderovski D.P., Penninger J.M., Kroemer G. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999, 397:441-446.
46. Razandi M., Pedram A., Merchenthaler I., Greene G.L., Levin E.R. Plasma membrane estrogen receptors exist and functions as dimers. Mol. Endocrinol. 2004, 18:2854-2865.
47. Cortot A., Armand J.P., Soria J.C. PI3K-AKT-mTOR pathway inhibitors. Bull. Cancer 2006, 93:19-26.
48. Yap T.A., Garrett M.D., Walton M.I., Raynaud F., de Bono J.S., Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr. Opin. Pharmacol. 2008, 8:393-412.
49. LoPiccolo J., Blumenthal G.M., Bernstein W.B., Dennis P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat. 2008, 11:32-50.
50. Hurst-Kennedy J., Boyan B.D., Schwartz Z. Lysophosphatidic acid signaling promotes proliferation, differentiation, and cell survival in rat growth plate chondrocytes. Biochim. Biophys. Acta 2009, 1793:836-846.
51. Pelekanou V., Notas G., Kampa M., Tsentelierou E., Radojicic J., Leclercq G., Castanas E., Stathopoulos E.N. ERalpha36, a new variant of the ERalpha is expressed in triple negative breast carcinomas and has a specific transcriptomic signature in breast cancer cell lines. Steroids 2012, 77:928-934.